1. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157(4 suppl):1.

2. Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 2006; 163:1905.

3. Mann, JJ. the medical management of depression. N Engl J Med, 2005; 353:1819.

4. Risch, N, Herrell, R, Lehner, T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. JAMA, 2009; 301(23):2462-2471.

5. Kinney, DK, Tanaka, M. An evolutionary hypothesis of depression and its symptoms, adaptive value, and risk factors.  J Nerv Ment Dis, 2009; 197(8):561-567.

6. Solomon, DA< Keller, MB, Leon, AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry, 2000; 157:229.

7. Andrews, PW, Thomason, JA Jr. The bright side of being blue: depression as an adaptation for analyzing complex problems. Psychol Rev, 2009; 116(3):620-654.

8. Mitchell, AJ. Depressed patients and treatment adherence. Lancet, 2006; 367:2041.

9. Jorm, AF, Morgan, AJ, Hetrick, SE. Relaxation for depression. Cochrane Database Syst Rev, 2008; CD007142.

10. Faulconbridge, LF,Wadden, TA, Berkowitz, RI, et al. Changes in symptoms of depression with weight loss: results of a randomized trial. Obesity (in press).

11. Haeffel, GJ, Getchell, M, Koposov, RA, et al. Association between polymorphisms in the dopamine transporter gene and depression: evidence for a gene-environment interaction in a sample of juvenile detainees. Psychological Science, 2008; 19(1):62-69.

12. Lowry, CA, Hollis, JH, deVries, A, et al. Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. Neuroscience, 2007; 146(2):756-772.

13. Pampallona, S, Bollini, P, Tibaldi, G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry, 2004; 61:714.

14. Lu, PH, Edland, SD, Teng, E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 2009; 72(24):2115-2121.

15. Smith, L, Walker, A, Gilhooly, K. Clinical guidelines of depression: a qualitative study of GP’s views. J Fam Pract, 2004; 53(7):556-561.

16. Lin, EH, Katon, WJ, VonKorff, M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 1998; 7:443.

17. Geddes, JR, Carney, SM, Davies, C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 2003; 361:653.

18. Lichtman, JH, Bigger, JT Jr, Blumenthal, JA, et al. Depression and coronary heart disease: recommendations for screening, referral and treatment. Circulation, 2008; 118(7):1768-1775.

19. Gartlehner, G, Gaynes, Bn, Hansen, RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med, 2008; 149:734.

20. Zimmerman, M, Galione, JN, Chelminski, I, et al. A simpler definition of major depressive disorder. Psychol Med, 2009 (July 23): 1-7.

21. Ali, S, Garg, SK, Cohen, BE, Bhave, P, Harris, WS, Whooley, MA. Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: data from the Heart and Soul Study. Psychother Psychosom, 2009; 78(2):125-127.

22. Mezuk, B, Eaton, WW, Albrecht, S, Golden, SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care, December 2008; 31(12):2383-2390.

23. Kroenke, K, Bair, MJ, Damush, TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA, 2009; 301(20):2099-2110.